AmplioVox

AmpliVox Therapeutics is a biotechnology company dedicated to developing regenerative medicines for the treatment of sensorineural hearing loss. The company's approach focuses on using small molecule inhibitors to modulate the Notch signaling pathway, a key biological regulator of cell fate in the inner ear. By inhibiting Notch signaling, AmpliVox aims to trigger the conversion of supporting cells into functional sensory hair cells, thereby restoring hearing in patients with permanent auditory damage. Founded by pioneers in the field of otology from Harvard Medical School and MIT, the company is currently advancing its lead candidates through pre-clinical development to address a significant unmet need in auditory health.